Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Other Non-Current Liabilities: 2010-2024

Historic Other Non-Current Liabilities for Ligand Pharmaceuticals (LGND) over the last 15 years, with Dec 2024 value amounting to $30.2 million.

  • Ligand Pharmaceuticals' Other Non-Current Liabilities fell 33.35% to $19.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.9 million, marking a year-over-year decrease of 33.35%. This contributed to the annual value of $30.2 million for FY2024, which is 8.66% up from last year.
  • Ligand Pharmaceuticals' Other Non-Current Liabilities amounted to $30.2 million in FY2024, which was up 8.66% from $27.8 million recorded in FY2023.
  • Ligand Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $30.9 million for FY2020, and its period low was $21.8 million during FY2021.
  • In the last 3 years, Ligand Pharmaceuticals' Other Non-Current Liabilities had a median value of $27.8 million in 2023 and averaged $28.6 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Other Non-Current Liabilities spiked by 37.30% in 2020, and later fell by 29.53% in 2021.
  • Ligand Pharmaceuticals' Other Non-Current Liabilities (Yearly) stood at $30.9 million in 2020, then declined by 29.53% to $21.8 million in 2021, then increased by 27.61% to $27.8 million in 2022, then remained steady at $27.8 million in 2023, then grew by 8.66% to $30.2 million in 2024.